Gilead Sciences, Inc. [NASDAQ: GILD] gained 0.10% or 0.07 points to close at $73.02 with a heavy trading volume of 6057572 shares. The company report on February 27, 2024 at 10:00 AM that Gilead Announces Funding Initiative to Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.
– 19 Organizations Will Receive a Total of $12.6 Million in Grant Funding Through Gilead’s Setting the P.A.C.E. Initiative –.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced it is providing a total of $12.6 million in grant funding to 19 organizations working to improve the HIV landscape for Black women and girls in the United States. These grants are a part of Gilead’s new Setting the P.A.C.E. (Prevention, Arts and Advocacy, Community, Education) initiative, a three-year commitment toward increasing HIV prevention, anti-stigma and health equity efforts for Black cisgender and Transgender women and girls, who are disproportionately impacted by the HIV epidemic.
The daily chart for GILD points out that the company has recorded -5.00% loss over the past six months.
If we look at the average trading volume of 7.36M shares, GILD reached to a volume of 6057572 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Gilead Sciences, Inc. [GILD]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for GILD shares is $86.28 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on GILD stock is a recommendation set at 2.23. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Truist have made an estimate for Gilead Sciences, Inc. shares, keeping their opinion on the stock as Hold, with their previous recommendation back on February 22, 2024. While these analysts kept the previous recommendation, Deutsche Bank raised their target price to Hold. The new note on the price target was released on November 09, 2023, representing the official price target for Gilead Sciences, Inc. stock. Previously, the target price had yet another raise from $88 to $95, while BofA Securities kept a Buy rating on GILD stock.
The Average True Range (ATR) for Gilead Sciences, Inc. is set at 1.45, with the Price to Sales ratio for GILD stock in the period of the last 12 months amounting to 3.36. The Price to Book ratio for the last quarter was 3.98, with the Price to Cash per share for the same quarter was set at 6.70. Price to Free Cash Flow for GILD in the course of the last twelve months was 12.26 with Quick ratio for the last quarter at 1.27.
Trading performance analysis for GILD stock
Gilead Sciences, Inc. [GILD] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.36. With this latest performance, GILD shares dropped by -8.17% in over the last four-week period, additionally sinking by -5.00% over the last 6 months – not to mention a drop of -9.47% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GILD stock in for the last two-week period is set at 37.65, with the RSI for the last a single of trading hit 38.75, and the three-weeks RSI is set at 38.98 for Gilead Sciences, Inc. [GILD]. The present Moving Average for the last 50 days of trading for this stock 79.12, while it was recorded at 73.10 for the last single week of trading, and 77.71 for the last 200 days.
Gilead Sciences, Inc. [GILD]: A deeper dive into fundamental analysis
Gilead Sciences, Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.27 and a Current Ratio set at 1.43.
Gilead Sciences, Inc. [GILD]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Gilead Sciences, Inc. posted 1.37/share EPS, while the average EPS was predicted by analysts to be reported at 1.54/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -11.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GILD. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Gilead Sciences, Inc. go to 5.12%.
An analysis of Institutional ownership at Gilead Sciences, Inc. [GILD]
The top three institutional holders of GILD stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in GILD stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in GILD stock with ownership which is approximately 5.8325%.
